Immunodetection of phosphorylation sites gives new insights into the mechanisms underlying phospholamban phosphorylation in the intact heart by Mundiña-Weilenmann, Cecilia et al.
Immunodetection of Phosphorylation Sites Gives New Insights into
the Mechanisms Underlying Phospholamban Phosphorylation in the
Intact Heart*
(Received for publication, August 29, 1996, and in revised form, September 26, 1996)
Cecilia Mundiña-Weilenmann‡, Leticia Vittone‡, Manuel Ortale§, Gladys Chiappe de Cingolani‡,
and Alicia Mattiazzi‡¶
From the Centro de Investigaciones Cardiovasculares, Facultad de Ciencias Médicas, Universidad Nacional de La Plata,
60 y 120, 1900 La Plata, Argentina
Phosphorylation site-specific antibodies, quantifica-
tion of 32P incorporation into phospholamban, and si-
multaneous measurements of mechanical activity were
used in Langendorff-perfused rat hearts to provide fur-
ther insights into the underlying mechanisms of phos-
pholamban phosphorylation. Immunological detection
of phospholamban phosphorylation sites showed that
the isoproterenol concentration-dependent increase in
phospholamban phosphorylation was due to increases
in phosphorylation of both Ser16 and Thr17 residues.
When isoproterenol concentration was increased at ex-
tremely low Ca21 supply to the myocardium, phospho-
rylation of Thr17 was virtually absent. Under these con-
ditions, 32P incorporation into phospholamban, due to
Ser16, decreased by 50%. Changes in Ca21 supply to the
myocardium either at constant b-adrenergic stimula-
tion or in the presence of okadaic acid, a phosphatase
inhibitor, exclusively modified Thr17 phosphorylation.
Changes in phospholamban phosphorylation due to ei-
ther Ser16 and/or Thr17 were paralleled by changes in
myocardial relaxation. The results indicate that cAMP-
(Ser16) and Ca21-calmodulin (Thr17)-dependent path-
ways of phospholamban phosphorylation can occur in-
dependently of each other. However, in the absence of
b-adrenergic stimulation, phosphorylation of Thr17
could only be detected after simultaneous activation of
Ca21-calmodulin-dependent protein kinase and inacti-
vation of phosphatase. It is suggested that under phys-
iological conditions, this requisite is only filled by cAMP-
dependent mechanisms.
Cardiac sarcoplasmic reticulum (SR)1 Mg21-dependent
Ca21-activated ATPase is regulated by phospholamban, a pro-
tein also located in the SR membranes. Phospholamban, which
normally associates with the Ca21 pump inhibiting its func-
tion, is critically involved in the regulation of cardiac contrac-
tion and relaxation. Phosphorylation of phospholamban by ei-
thercAMP-dependentproteinkinase (PKA)orCa21-calmodulin-
dependent protein kinase (CaMKII) causes dissociation of
phospholamban from the pump, thus increasing ATPase activ-
ity and the rate of Ca21 uptake by the SR (1, 2). The increased
rate of SR Ca21 uptake enhances the rate of the Ca21 transient
decline and increases the Ca21 available for subsequent re-
lease, inducing increases in cardiac relaxation and contractil-
ity, respectively. In vitro experiments indicate that PKA and
CaMKII phosphorylate phospholamban at two different sites,
Ser16 and Thr17, respectively (3). These phosphorylations are
independent of each other, and when both are operating, they
appear to have an additive action (4). In the intact heart,
b-adrenergic stimulation phosphorylates phospholamban at
both sites (5), which indicates that PKA- and CaMKII-depend-
ent pathways are also working in the functioning heart.
Whether these phosphorylation mechanisms are independent
of each other and additive, as described in the isolated SR
membranes, remains unknown. Different attempts to phospho-
rylate phospholamban by CaMKII in the intact heart have
systematically failed unless cAMP levels within the cell in-
crease (6–11). This consistent finding strongly suggests an
interaction between PKA and CaMKII pathways of phospho-
lamban phosphorylation in the intact heart. The nature of this
interaction as well as the cause for the difference between the
in vivo and in vitro results have never been explored.
The availability of phosphorylation-site specific antibodies to
phospholamban, which precisely discriminate between Ser16
and Thr17 phosphorylation sites (12), prompted us to reex-
amine the issue. Combination of this technique with the
quantitative assessment of phospholamban phosphorylation
by radiochemical labeling of ATP pools and simultaneous
measurements of mechanical parameters allowed us to char-
acterize the PKA and CaMKII-dependent mechanisms of
phospholamban phosphorylation in the intact heart and their
relative physiological roles on cardiac performance.
EXPERIMENTAL PROCEDURES
Heart Perfusions—Experiments were performed in isolated hearts
from male Wistar rats (250–350 g body wt) perfused according to the
Langendorff technique as described previously (8). The composition of
the physiological salt solution (PSS) was (in mM): 128.3 NaCl, 4.7 KCl,
1.35 CaCl2, 20.2 NaHCO3, 0.4 NaH2PO4, 1.1 MgCl2, 11.1 glucose, and
0.04 Na2EDTA. This solution was equilibrated with 95% O2, 5% CO2 to
give a pH of 7.4. The mechanical activity of the heart was assessed by
either sewing an isometric strain gauge arch (Micro Measurements,
type MA-06–030LB-120) to the left ventricular wall or passing into the
left ventricle a latex balloon connected to a pressure transducer (Namic,
perceptor DT disposable transducer). The initial length of the gauge
was set by stretching the segment attached by approximately 30%. The
balloon was filled with aqueous solution to achieve a left ventricular
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end-diastolic pressure of 8–14 mm Hg. No differences were observed
between the mechanical data obtained by measuring either the isomet-
ric tension or the isovolumic pressure, and they were considered to-
gether for statistical analysis. Hearts were perfused with PSS for 10–15
min for stabilization and then for the next 4 min with either PSS
(control) or different interventions, as described under “Results.” To
quantify 32P incorporation into phospholamban, hearts were perfused
for 60 min with recirculation with PSS containing 10 mCi/ml 32Pi after
the stabilization period and previously to the interventions assessed. At
the end of the experimental period, the ventricles were freeze-clamped,
pulverized, and stored at 270 °C until biochemical assay.
Preparation of SR Membrane Vesicles—Membrane vesicles were pre-
pared as described previously (8), except that the pulverized tissue from
each heart was homogenized in 6 volumes of a medium containing (in
mM): 30 KH2PO4 (pH 7.0), 5 Na2EDTA, 25 NaF, 300 sucrose, 1 phen-
ylmethylsulfonyl fluoride, and 1 benzamidine. Samples from 32P-la-
beled perfused hearts were homogenized in the same medium except
that the phosphate was replaced by 20 mM Tris-HCl (pH 7.0). Protein
was measured by the method of Bradford (13) using bovine serum
albumin as standard. The yield was 1–2 mg of membrane vesicles
protein per g of cardiac tissue.
Electrophoresis and Western Blot Analysis—SDS-PAGE was per-
formed using 10% acrylamide slab gels according to Porzio and Pearson
(14) as described previously (8). Samples for electrophoresis were not
boiled unless stated. For immunological detection of phospholamban
phosphorylation sites, 10 mg of membrane protein were electrophoresed
per gel lane. Proteins were transferred to PVDF membranes (Immo-
bilon-P, Millipore) and probed according to Drago and Colyer (12) with
monoclonal antibody to phospholamban (1:5000) or polyclonal antibod-
ies raised to a phospholamban peptide (residues 9–19) phosphorylated
at Ser16 (1:10,000) or at Thr17 (1:5000) (PhosphoProtein Research, UK).
Immunoreactivity was visualized by peroxidase-conjugated antibodies
using a peroxidase-based chemiluminescence detection kit (Boehringer
Mannheim, Germany). The signal intensity of the bands on the film was
quantified by optical densitometric analysis. To assess 32P incorpora-
tion into phospholamban, 300 mg of membrane protein were electro-
phoresed per gel lane. Gels were run in duplicate in order to use one of
them for autoradiography and the other for liquid-scintillation count-
ing. Quantitative results were expressed as pmol of 32P incorporated
into phospholamban per mg of SR protein based on the specific activity
of 32P in phosphocreatine (15).
Phosphorylation of Isolated SR Membranes—Phosphorylation of SR
membrane vesicles was carried out at 30 °C in 0.1 ml of reaction
medium containing 50 mg SR protein, 50 mM Tris-HCl (pH 7.0), 5 mM
EGTA, 5 mM Mg-acetate, and 200 mM ATP. PKA-dependent phospho-
rylation was catalyzed by 30 units/ml of the PKA-catalytic subunit.
Alternatively, PKA-catalytic subunit and EGTA were omitted, and
phosphorylation was carried out by the endogenous CaMKII present in
the SR membranes in the presence of 0.5 mM Cl2Ca, 1 mM calmodulin,
and 1 mM protein kinase A inhibitor peptide 5–24 amide. Reaction was
stopped after 1 min (PKA) or 5 min (CaMKII) with SDS sample buffer.
Other Assays—Myocardial cAMP content was measured as described
previously (8) by radioimmunoassay (16) using a commercially avail-
able kit (DuPont NEN) with acetylation of the samples. Results are
expressed as pmol of cAMP per mg of wet weight. PP1 activity was
assayed by measuring dephosphorylation of 32P-labeled phosphorylase
a (17). One activity unit was that amount of enzyme that catalyzes the
release of 1 mmol of 32P/min.
Statistics—All data are expressed as the mean 6 S.E. of n prepara-
tions. Student’s t test for paired or unpaired observations (mechanical
and biochemical results, respectively) was used to test for statistical
differences. p , 0.05 was considered statistically significant.
RESULTS
Immunodetection of Site-specific Phosphorylated Phospho-
lamban—Specific antibodies to phospholamban, Ser16 and
Thr17-phosphorylated phospholamban peptides, were tested in
SR membrane vesicles phosphorylated by the catalytic subunit
of PKA or by the endogenous SR CaMKII (Fig. 1). The mono-
clonal antibody to phospholamban identified both the pentam-
eric form of phospholamban (Fig. 1A, lanes a and c) and the
monomeric form obtained by boiling the sample prior to elec-
trophoresis (Fig. 1A, lanes b and d). Antibody to Ser16 phos-
phopeptide only recognized phospholamban phosphorylated by
PKA (Fig. 1B, lanes a and b) and ignored CaMKII-phosphoryl-
ated phospholamban (Fig. 1B, lanes c and d). Conversely, an-
tibody to Thr17 phosphopeptide exclusively recognized
CaMKII-phosphorylated phospholamban (Fig. 1C, lanes c and
d). Antibodies to Ser16 phosphopeptide and to Thr17 phos-
phopeptide did not recognize unphosphorylated phospholam-
ban (data not shown).
Isoproterenol Concentration-dependent Induced Increase in
Phospholamban Phosphorylation. Independence of the PKA
Cascade—Fig. 2, panel A, shows an autoradiograph of SRmem-
brane vesicles isolated from hearts perfused with 32P in control
conditions and in the presence of 3, 30, and 300 nM isoproter-
enol. Isoproterenol increased phosphorylation of phospholam-
ban and reached a “plateau” at 30 nM. Panel B shows overall
results of this experimental series.
Fig. 3A, upper panel, shows immunoblots of SR membrane
vesicles obtained from hearts perfused with increasing isopro-
terenol concentrations under conditions of normal calcium sup-
ply to the myocardium (1.35 mM [Ca]o). b-adrenergic stimula-
tion induced phosphorylation of both Ser16 and Thr17 residues
of phospholamban. Mean values of Ser16 and Thr17 phospho-
lamban phosphorylation obtained from optical densitometric
analysis of three different experiments of this type are shown
by the open symbols in Fig. 3B. The results indicate that the
isoproterenol concentration-dependent increase in phospho-
lamban phosphorylation (Fig. 2) is due to an isoproterenol
concentration-dependent increase in the phosphorylation of
both Ser16 and Thr17 residues. In all cases, a maximum was
reached at 30 nM isoproterenol. Table I shows mean values of
intracellular cAMP levels and of mechanical parameters ob-
tained at the different isoproterenol concentrations.
In an attempt to diminish Ca21 supply to the myocardium
and therefore block phospholamban phosphorylation by
CaMKII, hearts were perfused with the same isoproterenol
concentrations as above but in the presence of 0.07 mM [Ca]o
plus 400 nM nifedipine. Myocardial contractility was abolished
at any of the isoproterenol concentrations studied. Under these
conditions, an isoproterenol concentration-dependent phospho-
rylation of Ser16 was observed without detectable changes in
FIG. 1. Immunodetection of site-specific phosphorylated phos-
pholamban. Cardiac SR membrane vesicles were phosphorylated with
200 mM ATP at 30 °C by either 30 units/ml of the catalytic subunit of
cAMP-dependent protein kinase (PKA, lanes a and b) or in the presence
of 0.5 mM Cl2Ca and 1 mM calmodulin to stimulate the intrinsic Ca
21-
calmodulin-dependent protein kinase activity (CaMKII, lanes c and d).
Reaction was stopped either after 1 min (PKA) or 5 min (CaMKII) with
SDS sample buffer. Samples were solubilized at room temperature
(lanes a and c) or at 100 °C for 5 min (lanes b and d). 10 mg of protein
were loaded onto each lane of SDS-PAGE gels. Proteins were trans-
ferred to PVDF membranes. Blots were probed with monoclonal anti-
body to phospholamban (1:5000, panel A, PHL), or polyclonal antibodies
to Ser16 phosphopeptide (1:10000, panel B, PSer16-PHL) and Thr17
phosphopeptide (1:5000, panel C, PThr17-PHL). Antibody binding was
visualized using a chemiluminescence detection kit. PHLH and PHLL
designate the pentameric and monomeric forms of phospholamban,
respectively.
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phosphorylation of Thr17 (Fig. 3A, lower panel). Mean results of
three different experiments of this type are shown by the filled
symbols in Fig. 3B. At each isoproterenol concentration, Ser16
was phosphorylated to the same extent, independently of the
degree of CaMKII-induced phosphorylation of Thr17. These
findings indicate that PKA-dependent phospholamban phos-
phorylation is independent of the CaMKII pathway in the
intact functioning heart.
Additivity of PKA- and CaMKII-dependent Phosphorylation
of Phospholamban in the Intact Heart—To study the relative
contribution of both phosphorylation sites to the total phospho-
lamban phosphorylation after b-adrenoreceptor stimulation,
hearts were perfused with 32P, and phosphorylation of phos-
pholamban was quantified at the “plateau” of the dose-re-
sponse curve to isoproterenol (30 nM), under conditions of nor-
mal [Ca]o (1.35 mM) and diminished Ca
21 supply to the
myocardium (0.25 mM [Ca]o and 0.07 mM [Ca]o plus 400 nM
nifedipine). The decrease in Ca21 supply gradually decreased
phospholamban phosphorylation (Fig. 4A) and myocardial re-
laxation without changes in cAMP levels (Table I). Immunode-
tection of the site-specific phosphorylated phospholamban re-
vealed that the decrease in phospholamban phosphorylation is
exclusively due to a decrease in Thr17 phosphorylation (Fig.
4B). Note that the isoproterenol-induced increase in Ser16
phosphorylation was the same at any of the [Ca21]o assayed.
Under conditions of extremely low Ca21 supply to the myocar-
dium, in which Thr17 phosphorylation was virtually absent,
total phospholamban phosphorylation decreased by approxi-
mately 50%. These findings demonstrate the additivity of PKA
and CaMKII pathways of phospholamban phosphorylation, in
agreement with the in vitro results (4). Furthermore, both
mechanisms contribute to the relaxant action of b-adrenergic
stimulation (Table I).
CaMKII-dependent Phospholamban Phosphorylation. Role of
Phosphatases—To address the participation of phosphatases in
the degree of phospholamban phosphorylation, rat hearts were
perfused with 32P at two different [Ca]o in the absence and in
the presence of the phosphatase inhibitor OA (0.1 mM). This OA
concentration decreased PP1 activity by 82.5 6 1.5%. Only in
the presence of OA did the increase in [Ca]o enhance phospho-
lamban phosphorylation (Fig. 5). This enhanced phosphoryla-
tion of phospholamban was associated with a significant in-
crease in contractility and a decrease in half relaxation time
(Table I). In 4 out of 11 experiments, the addition of OA at 3.85
mM [Ca]o produced a heart contracture. The cause for this
contracture was not explored in the present experiments but
might be due to the effects of OA on phosphatases other than
those regulating phospholamban phosphorylation (18, 19). The
failure to detect phospholamban phosphorylation after increas-
ing [Ca]o, in the absence of OA, was also observed when con-
tractility was increased by poststimulation potentiation (PSP)
(9) to levels similar to those evoked by maximal b-adrenergic
stimulation (PSP of 88 6 9% versus isoproterenol of 72 6 7%).
Phospholamban phosphorylation in pmol of 32P/mg of SR pro-
tein was: PSP, 20.0 6 1.0 and control, 24.7 6 1.2. Immunolog-
ical detection of the two phosphorylation sites of phospholam-
ban (Fig. 6A) showed that the increase in [Ca]o did not increase
phosphorylation of either Thr17 or Ser16 residues. The same
increase in [Ca]o in the presence of 1 mM OA increased phos-
phorylation of Thr17 without affecting Ser16 (Fig. 6A). This
FIG. 2. Isoproterenol concentration-
dependent increase in 32P incorpora-
tion into phospholamban. Panel A, au-
toradiograph of SR membrane vesicles
isolated from rat hearts perfused with 32P
and then without (lane a) or with differ-
ent isoproterenol concentrations (Iso,
lanes b to d). Samples (300 mg) were sub-
jected to SDS-PAGE and autoradiogra-
phy. PHLH and PHLL designate the pen-
tameric and monomeric forms of
phospholamban, respectively. Panel B,
isoproterenol dose-response curve for 32P
incorporation into phospholamban. Re-
sults are expressed as percentage of the
maximal 32P incorporation into phospho-
lamban achieved in each experimental se-
ries (n 5 4). Maximal 32P incorporation
into phospholamban was 278.0 6 26.1
pmol/mg of SR protein.
FIG. 3. Isoproterenol concentration-dependent increase in
phosphorylation of Ser16 and Thr17 residues of phospholamban.
Panel A, immunoblots of SR membrane vesicles isolated from hearts
perfused with different isoproterenol concentrations (Iso) at 1.35 mM
[Ca]o (Control [Ca]o) or at 0.07 mM [Ca]o 1 400 nM nifedipine (Low
[Ca]o). 10 mg of SR protein were resolved by SDS-PAGE and transferred
to PVDF membranes. Blots were probed with anti-Ser16 phosphopep-
tide (PSer16-PHL) and anti-Thr17 phosphopeptide (PThr17-PHL). Anti-
body binding was visualized using a chemiluminescence detection kit.
Panel B, mean 6 S.E. values obtained after the densitometric analysis
of the signal of three immunoblots. Results are expressed as percentage
of the maximal signal achieved in each experimental series. At low
[Ca]o, 30 nM isoproterenol at 1.35 mM [Ca]o, run in parallel, was re-
garded as 100%.
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concentration of OA decreased PP1 activity by 97.96 1.0%. The
overall results of this series are shown in Fig. 6B. These find-
ings indicate that in the intact functioning heart CaMKII-de-
pendent phospholamban phosphorylation can be detected in
the absence of intracellular cAMP increases, provided phos-
phatases are inhibited.
DISCUSSION
Phosphorylation site-specific antibodies are a novel experi-
mental tool to recognize a phosphorylated epitope of a protein.
The phosphorylation site-specific antibodies to phospholamban
(12) used in the present experiments failed to detect the un-
phosphorylated protein and proved to be highly specific in the
discrimination between the two sites of phosphorylation of
phospholamban since no cross-reactivity with the other site of
phosphorylation was observed (Fig. 1). The combination of this
technique with the classical isotopic labeling technique of
quantification of phospholamban phosphorylation, along with
simultaneous measurements of mechanical parameters, al-
lowed us a detailed characterization of the two signaling cas-
cades of phospholamban phosphorylation, the relationships be-
tween them, and their physiological significance in the intact
heart.
In agreement with the in vitro findings, the present results
demonstrate that in the intact functioning heart, PKA- and
CaMKII-dependent pathways of phospholamban phosphoryla-
tion may work independently of each other (Figs. 3 and 6) and
that when both mechanisms are operating they have an addi-
tive action (Fig. 4). Previous works have consistently shown
that CaMKII-dependent phospholamban phosphorylation and
changes in myocardial relaxation can only occur in the intact
heart when cAMP levels within the cell increase (7–11). This
finding was interpreted as an interrelationship between PKA
and CaMKII cascades, which would favor dual site phosphoryl-
ation of phospholamban after b-adrenoreceptor stimulation.
This conclusion was in sharp contrast with the independence of
both pathways described in the in vitro systems. The reason for
the apparent discrepancy between the in vitro and the in vivo
results as well as the nature of the interaction between the two
phosphorylation cascades in the intact heart are not yet under-
stood. Several mechanisms have been considered to explain
this interaction, among which are the following. 1) Only the
increases in intracellular Ca21 evoked by cAMP-dependent
mechanisms are large enough to activate CaMKII pathway. 2)
CaMKII cascade could be activated only by compartmentalized
increases in Ca21 evoked by cAMP increases. 3) CaMKII could
be activated by cAMP-dependent mechanisms unrelated to in-
tracellular Ca21 increase. 4) Phosphatases that dephosphoryl-
ate phospholamban could be inhibited by a PKA-dependent
mechanism. The fact that increases in contractility (reflecting
cytosolic Ca21) similar to that evoked by isoproterenol, i.e. PSP,
failed to phosphorylate phospholamban allows to rule out the
first possibility. Similar conclusions were previously obtained
(9). Furthermore, and relevant to the first three possibilities,
we are presenting evidence showing that activation of CaMKII
cascade and phosphorylation of Thr17 residue could be detected
even in the absence of high cAMP levels (Fig. 6). The present
findings give support to the fourth hypothesis. Our results
indicate that the nature of the interaction between PKA and
CaMKII cascades of phospholamban phosphorylation lies in a
basic mechanism underlying any phosphorylation process, i.e.
the degree of phosphatase activity in the different experimen-
tal conditions. The major phosphatase that dephosphorylates
phospholamban is a form of PP1 associated to the SR (20).
Phosphorylation of Thr17 residue in the intact heart could be
TABLE I
Effects of different interventions on mechanical parameters and intracellular cAMP levels in the intact heart
Rat hearts were perfused with the indicated interventions and then freeze-clamped and processed as described under “Experimental Proce-
dures.” Results are mean 6 SEM of n hearts (parentheses). PSS: physiological salt solution; Nife: nifedipine; ND: not determined. D, indicate
differences with respect to control. Control for mechanical data are values obtained immediately before the intervention. Control for biochemical
data are values obtained in the PSS group.
Treatment Maximal rate ofcontraction
Half relaxation
time cAMP
% of control D msec pmol/mg wet wt
PSS




1.35 mM [Ca]o 135.21 6 7.02
a 210.75 6 0.90a 1.097 6 0.036a
(10) (10) (3)
30 nM
1.35 mM [Ca]o 172.42 6 7.01
a 219.95 6 1.78a 1.696 6 0.054a
(9) (19) (6)
300 nM
1.35 mM [Ca]o 187.52 6 21.17
a 219.11 6 0.56a 1.759 6 0.204a
(10) (10) (3)
30 nM
0.25 mM [Ca]o 106.05 6 8.80 29.67 6 1.69
a 1.692 6 0.096a
(9) (9) (3)
30 nM




3.85 mM [Ca]o 135.57 6 8.91




1.35 mM [Ca]o 104.95 6 5.33 20.80 6 2.86 ND
(9) (7)
0.1 mM
3.85 mM [Ca]o 160.47 6 10.18
a 28.57 6 3.87 0.759 6 0.142
(7) (7) (3)
a p , 0.05 when compared to control.
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detected in two situations, at high intracellular cAMP levels
and in the presence of OA. It has been proposed that SR-
associated PP1 could be inhibited by PKA-dependent phospho-
rylation by two different but related mechanisms. First, as
described for PP1 associated to glycogen particles (21) and to
SR in skeletal muscle (22, 23), PKA phosphorylation of the
PP1-regulatory subunit would release the catalytic (C)-sub-
unit, which would prevent PP1 from dephosphorylating phos-
pholamban (20). Second, the thermostable protein inhibitor 1,
when phosphorylated by PKA, becomes a potent inhibitor of
PP1 C-subunit (24). Evidence for an isoproterenol-induced
phosphorylation and increased activity of inhibitor 1 and for a
reduction in SR-associated PP1 activity have been reported in
the intact heart and isolated myocytes (25–27). PP1 is also
FIG. 4. Effects of decreasing Ca21supply to the myocardium on isoproterenol-induced phospholamban phosphorylation. Panel A,
left, autoradiograph of SR membranes isolated from rat hearts perfused with 32P in the absence (lane a) or the presence (lanes b to d) of 30 nM
isoproterenol (Iso) simultaneously given with interventions that gradually decrease the Ca21 supply to the myocardium, low [Ca]o with or without
nifedipine (Nife). PHLH and PHLL designate the pentameric and monomeric forms of phospholamban, respectively. Panel A, right, overall results
(n 5 3) of 32P incorporation into phospholamban obtained under the experimental conditions depicted by the autoradiograph. Results are expressed
as percentage of the maximal 32P incorporation into phospholamban achieved in each experimental series. Maximal 32P incorporation into
phospholamban was 184.0 6 8.0 pmol/mg of SR protein. Panel B, blots and overall results of the immunodetection of the site-specific phospho-
rylated phospholamban (PSer16-PHL and PThr17-PHL) after the same treatment. Mean 6 S.E. values of the densitometric analysis of the signal
of three immunoblots are shown. Results are expressed as percentage of the maximal signal achieved in each experimental series.
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inhibited by OA (18). We have found that increases in [Ca]o, in
the presence of OA, phosphorylated phospholamban exclu-
sively in Thr17. This phosphorylation was associated to a de-
crease in half relaxation time. Higher OA concentrations were
described to produce an increase in phospholamban phospho-
rylation and an enhanced myocardial relaxation (28). A faster
intracellular Ca21 decline induced by OA has also been ob-
served in isolated myocytes (29). Unfortunately, none of these
studies looked for sites of phosphorylation of phospholamban.
In the present results, both situations in which we were able to
detect Thr17 phosphorylation, high cAMP and OA, have a com-
mon feature, and this is the inhibition of phosphatases.
In contrast to the in vivo results, phosphatase inhibition was
not required to detect phosphorylation of either Ser16 or Thr17
residues of phospholamban in the in vitro systems (Fig. 1). This
might be due to the already low phosphatase activity of the SR
membrane preparation commonly used for the in vitro assays.
It has been shown that PP1 activity decreased during the
standard procedure of isolation of SR membrane vesicles (20)
and that high salt treatment (used to wash out the membranes
from myofibrillar proteins) also inhibits SR-associated PP1
activity (22).
For several years, different laboratories including our own,
attempted to define the physiological role of the CaMKII path-
way of phosphorylation of phospholamban (6–11, 29). We are
presenting evidence that indicate that both phosphorylation of
phospholamban as well as the physiological expression of this
phosphorylation, i.e. the increase in myocardial relaxation and
the consequent increase in contractility, requires simultaneous
stimulation of protein kinases and inhibition of phosphatases.
Physiologically, this requisite is only filled by b-adrenergic
stimulation. Although in the absence of high intracellular
cAMP levels, the physiological meaning of CaMKII cascade
appears as negligible, in its presence it is not. The present
results indicate that under maximal b-adrenergic stimulation,
activation of CaMKII cascade accounts for about 50% of phos-
FIG. 5. Increasing [Ca]o in the pres-
ence of okadaic acid enhanced phos-
pholamban phosphorylation. Left, SR
membranes were isolated from 32P-per-
fused rat hearts at two different [Ca]o in
the absence (lanes a and b) or the pres-
ence (lanes c and d) of 0.1 mM okadaic acid
(OA). Samples (300 mg) were subjected to
SDS-PAGE and autoradiography. PHLH
designates the pentameric form of phos-
pholamban. Right, bars show overall re-
sults of 32P incorporation into phospho-
lamban. The number of experiments in
each treatment group is indicated in
parentheses.
FIG. 6. Increasing [Ca]o in the pres-
ence of okadaic acid enhanced phos-
phorylation of Thr17 residue of phos-
pholamban. Panel A, immunoblots
probed with anti-Ser16 phospholamban
phosphopeptide (top, PSer16-PHL) and
anti-Thr17 phospholamban phosphopep-
tide (bottom, PThr17-PHL) of SR mem-
branes isolated from hearts perfused with
1 mM okadaic acid (OA) at different [Ca]o.
PHLH and PHLL designate the pentam-
eric and monomeric forms of phospholam-
ban, respectively. Panel B, mean 6 S.E.
values obtained after the densitometric
analysis of the signal of four immuno-
blots. Results are expressed as percentage
of the isoproterenol (Iso)-induced site-spe-
cific phosphorylation, run in parallel.
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pholamban phosphorylation. This CaMKII-induced phospho-
lamban phosphorylation is closely associated with an increase
in the relaxant capacity of the intact ventricle.
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